Buch, Englisch, 375 Seiten, Previously published in hardcover, Format (B × H): 152 mm x 229 mm, Gewicht: 1250 g
Buch, Englisch, 375 Seiten, Previously published in hardcover, Format (B × H): 152 mm x 229 mm, Gewicht: 1250 g
ISBN: 978-1-61737-737-2
Verlag: Humana Press
Biopharmaceutical Drug Design and Development, Second Edition, furthers the widely successful first edition, published in 1999. This new, expanded edition investigates the dozens of new biopharmaceutical drugs that have become available since that time. Among the drugs discussed are ones in the categories of monoclonal antibodies for in-vivo use, cytokines, growth factors, enzymes, immunomodulators, thrombolytics, and immonotherapies including vaccines. Additionally, the volume examines new and emerging technologies, such as bioinformatics, DNA microarrays, transgenics, therapeutic gene delivery, stem cells, nucleic acid-based therapeutics, and macromolecular drug delivery. Authors also study pharmacogenetics in the clinic and changes in biologic drug approval at the FDA. Biopharmaceutical Drug Design and Development, Second Edition, is a worthy sequel to a discussion on the dynamic, exciting field of biotechnology.
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Biotechnology: 2008 and Beyond.- The Human Genome Project and Drug Development.- The Use of Bioinformatics and Chemogenomics in Drug Discovery.- DNA Microarrays in Drug Discovery and Development.- Microarray Technology Using Proteins, Cells, and Tissues.- Pharmacogenetic Issues in Biopharmaceutical Drug Development.- Development and Applications of Transgenics in Biotechnology and Medicine.- Viral, Nonviral, and Physical Methods for Gene Delivery.- Stem Cell Technology and Drug Development.- Small Nucleic Acid-Based Drugs: Successes and Pitfalls.- Therapeutic Strategies Targeting the Innate Antiviral Immune Response.- Pharmacogenetics in the Clinic.- Molecular Modeling: Considerations for the Design of Pharmaceuticals and Biopharmaceuticals.- Macromolecular Drug Delivery.- Changes in Biologic Drug Approval at FDA.- Follow-On Protein Products: The Age of Biogenerics?.